Primary Immune Deficiency (PID) - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 70
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Primary Immune Deficiency (PID) - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Primary Immune Deficiency (PID) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Primary Immune Deficiency (PID) . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Primary Immune Deficiency (PID) for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Primary Immune Deficiency (PID) market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Primary Immune Deficiency (PID) , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Primary Immune Deficiency (PID) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Primary Immune Deficiency (PID) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Primary Immune Deficiency (PID) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Primary Immune Deficiency (PID) covering 7MM from 2015-2025.

  • Segment level epidemiology and market split for Primary Immune Deficiency (PID) .

  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Primary Immune Deficiency (PID) .

  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Primary Immune Deficiency (PID) market trends.

  • Thorough market distribution based on market share for Primary Immune Deficiency (PID) .

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Primary Immune Deficiency (PID) market.

  • To understand the future market competition in the Primary Immune Deficiency (PID) market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Primary Immune Deficiency (PID) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Primary Immune Deficiency (PID) - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Introduction

2. Primary Immune Deficiency (PID) Market Overview at a Glance
2.1. Total Market Share Distribution of Primary Immune Deficiency (PID) for 7 MM in 2016
2.2. Total Market Share Distribution of Primary Immune Deficiency (PID) for 7 MM in 2025

3. Primary Immune Deficiency (PID)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Primary Immune Deficiency (PID) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Primary Immune Deficiency (PID) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Primary Immune Deficiency (PID) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Primary Immune Deficiency (PID) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Primary Immune Deficiency (PID) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Primary Immune Deficiency (PID) in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Primary Immune Deficiency (PID)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Primary Immune Deficiency (PID) Market (2016 & 2025)

9. Primary Immune Deficiency (PID) : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Diagnosed Cases Primary Immune Deficiency (PID) in United States (2015-2025)
Table 2: Diagnosed Cases Primary Immune Deficiency (PID) in Germany (2015-2025)
Table 3: Diagnosed Cases Primary Immune Deficiency (PID) in France (2015-2025)
Table 4: Diagnosed Cases Primary Immune Deficiency (PID) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Primary Immune Deficiency (PID) in Spain (2015-2025)
Table 6: Diagnosed Cases Primary Immune Deficiency (PID) in Italy (2015-2025)
Table 7: Diagnosed Cases Primary Immune Deficiency (PID) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Primary Immune Deficiency (PID)
Table 9: List of Pipeline Phase III Drugs for Primary Immune Deficiency (PID)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 17: Germany Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 18: France Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 20: Spain Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 21: Italy Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Table 22: Japan Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)

List of Figures

Figure 1: Diagnosed Cases Primary Immune Deficiency (PID) in United States (2015-2025)
Figure 2: Diagnosed Cases Primary Immune Deficiency (PID) in Germany (2015-2025)
Figure 3: Diagnosed Cases Primary Immune Deficiency (PID) in France (2015-2025)
Figure 4: Diagnosed Cases Primary Immune Deficiency (PID) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Primary Immune Deficiency (PID) in Spain (2015-2025)
Figure 6: Diagnosed Cases Primary Immune Deficiency (PID) in Italy (2015-2025)
Figure 7: Diagnosed Cases Primary Immune Deficiency (PID) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Primary Immune Deficiency (PID)
Figure 9: List of Pipeline Phase III Drugs for Primary Immune Deficiency (PID)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 18: France Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Primary Immune Deficiency (PID) in USD, Million (2015-2025)
  • United States Hypertrophic Cardiomyopathy Therapeutics Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market ......
  • Raynauds Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 48
    Raynauds Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape. Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smok......
  • Batten Disease - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 53
    Batten Disease - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Batten Disease - Pipeline Review, H2 2017, provides an overview of the Batten Disease (Central Nervous System) pipeline landscape. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually......
  • Trigeminal Neuralgia - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 54
    Trigeminal Neuralgia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H2 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Visceral Pain - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 55
    Visceral Pain - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Visceral Pain - Pipeline Review, H2 2017, provides an overview of the Visceral Pain (Central Nervous System) pipeline landscape. Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or NSAIDs and pai......
  • Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 119
    Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape. Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important c......
  • Liver Cirrhosis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 90
    Liver Cirrhosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver wh......
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market Research Report 2017
    Published: 14-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hypertrophic Cardiomyopathy Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North A......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs